Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
Joseph F Merola, Philip Mease, Alan Kivitz et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3b, randomized, 52-week trial compared ixekizumab plus tirzepatide with ixekizumab alone in adults with active psoriatic arthritis and overweight with a weight-related comorbidity or obesity. At week 36, the combined endpoint of ACR50 response and at least 10% weight reduction was achieved by 31.7% with combination therapy versus 0.8% with ixekizumab alone (P < 0.001). ACR50 response was also higher with combination therapy (33.5% vs 20.4%; P = 0.02). Safety profiles were consistent with previous studies of the two drugs.
Key findings
- At week 36, ACR50 plus at least 10% weight reduction occurred in 31.7% with ixekizumab plus tirzepatide versus 0.8% with ixekizumab alone (P < 0.001).
- ACR50 response was 33.5% with combination therapy and 20.4% with ixekizumab alone (P = 0.02), with separation reported by week 4.
- Combination therapy improved patient-reported function and fatigue versus ixekizumab alone: HAQ-DI change ∆ -0.2 and FACIT-F improvement of 3.8.
Why it matters
The trial addresses concurrent inflammatory disease and excess weight in adults with active psoriatic arthritis. Its results suggest that adding tirzepatide to ixekizumab can improve joint response while also achieving substantial weight reduction, with reported gains in function and fatigue. This provides evidence about a combined approach to these linked clinical burdens, while the findings apply to the studied population and trial regimen.
What to keep in mind
The abstract reports outcomes at 36 weeks within a 52-week trial; longer-term durability is not described. The study included adults with active PsA and overweight or obesity, limiting direct applicability beyond this population.